The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Copanlisib for relapsed/refractory NHL: results of the CHRONOS-1 study
Copanlisib is a novel PI3K inhibitor, targeting both PI3K-α and PI3K-δ isoforms in malignant B-cells. It was granted FDA approval based on data from the Phase II CHRONOS-1 study (NCT01660451) investigating copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Here, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the longer term follow-up data being presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
